Arvinas, a biotech company specializing in targeted protein degradation drugs, will present its first quarter 2026 financial results and provide a corporate update on May 12, 2026, via a live webcast. The company is known for developing the first FDA-approved PROTAC drug, VEPPANU, for advanced breast cancer, and is advancing several investigational drugs for neurodegenerative diseases and cancers. Investors and interested parties can access the webcast on Arvinas' website, with a replay available after the event. This update is important as it offers insights into the company's progress and financial health amid ongoing drug development.
Yanik Guillemette, a Montreal-based entrepreneur and investment strategist, criticizes Canada's growing digital regulations, including the CRTC's proposal for streaming platforms to fund Canadian content. He argues these rules increase costs for cons...
Yanik Guillemette, a Canadian tech entrepreneur, criticizes Ottawa's increasing digital regulations, including a proposed 15% revenue tax on streaming platforms and laws C-11, C-18, and C-22. He argues these measures burden the tech ecosystem, raise ...
President Donald Trump stated that negotiations with Iran over its nuclear program are proceeding in an orderly and constructive manner. He emphasized the need for patience and warned against rushing the deal, maintaining the U.S. naval blockade on I...
Ripple's XRP exchange reserves on Binance have declined to about 2.70 billion XRP, reflecting reduced sell-side liquidity as investors move holdings off exchanges. This tightening supply coincides with strong institutional demand, with XRP ETFs accum...
Disc Medicine received a Complete Response Letter from the FDA rejecting its new drug application for bitopertin due to insufficient evidence, causing its stock to fall 22% on February 13, 2026. The Rosen Law Firm is investigating potential securitie...
